News & Media
News Updates
NEW YORK, December 12, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will
NEW YORK, November 20, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its
Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points
Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and
NEW YORK, October 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition
Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer account highlights accelerating adoption of the Company’s rapid, non-invasive drug
The Workplace Health & Safety Show (WHS Show) returns to Sydney this October as the flagship event in Australia’s leading series dedicated to workplace health and safety. Held during National Safe Work
Webinar: Thursday November 20th Time: 4PM AEDT | 9AM GST | 2PM JST | 10:30AM IST Discover a faster, non-invasive, and more efficient approach to workplace drug testing. See firsthand
The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in the second half of 2026 NEW YORK, September 26, 2025
In December 2024, INBS submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and clearance of its Intelligent Fingerprinting Drug Screening System. As expected, the FDA reviewed and responded with questions by issuing an Additional Information (AI) request in February 2025. This AI request consisted of over 70 items to be addressed by the Company. With the support of specialized FDA consultants and expert third-party partners, INBS responded to the FDA’s questions and submitted additional information in August 2025
Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth
Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global
Media Contact
For media enquiries, please contact marketing@ibs.inc.
Featured Media
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our innovative technology has been featured worldwide in leading news outlets and media platforms.
The Intelligent Fingerprinting Drug Screening System is revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
